Cost-effectiveness of various interventions for newly diagnosed diabetic macular edema.

ABSTRACT:

Objective

Anti-vascular endothelial growth factor therapies have revolutionized the treatment of clinically significant diabetic macular edema (CSDME); yet these agents are expensive, and whether they are cost-effective is unclear. The purpose of this study is to determine the most cost-effective treatment option for patients with newly diagnosed CSDME: focal laser photocoagulation alone (L), focal laser plus intravitreal ranibizumab (L+R), focal laser plus intravitreal bevacizumab (L+B), or focal laser plus intravitreal triamcinolone (L+T) injections.

Design

Cost-effectiveness analysis.

Participants

Hypothetical cohort of 57-year-old patients with newly diagnosed CSDME.

Methods

By using a Markov model with a 25-year time horizon, we compared the incremental co

SUBMITTER: Stein JD 

PROVIDER: S-EPMC3737388 | biostudies-literature | 2013 Sep

REPOSITORIES: biostudies-literature